Pulmonary Arterial Hypertension – Epidemiology Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pulmonary Arterial Hypertension – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Pulmonary Arterial Hypertension Disease Understanding

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

Report Scope

• The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool in 7MM

Key Topics Covered:

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Epidemiology Overview at a Glance

4.1. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017

4.2. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification of Pulmonary Arterial Hypertension (PAH)

5.3.1. WHO classification

5.3.2. Functional Classification of PAH

5.4. Etiology

5.5. Risk factors

5.6. Pathophysiology

5.7. Diagnosis

5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Population and Forecast Parameters

6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

7.1. The United States

7.2. Germany

7.3. France

7.4. Italy

7.5. Spain

7.6. The United Kingdom

7.7. Japan

8. Treatment Algorithm

8.1. Current Treatment Practices

8.2. Treatment Guidelines

8.2.1. CHEST Guidelines [The United States]

8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies

10.1. A Rare Case of Drug Induced PAH

10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Appendix

12.1. Bibliography

12.2. Report Methodology

13. Capabilities

14. Disclaimer

15. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/yja0jv

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900